Stock vs Stock Comparison

argenx SE vs AbbVie Inc.

ARGX wins the Tale of the Tape 6–3.

ARGX$813.14
ABBV$217.13

🏆 Tale of the Tape

63
ARGXABBV
31.1%Profitability (Net Margin)6.9%
37.1xValuation (P/E)106.2x
13.8%Efficiency (ROIC)8.3%
5/9Health (Piotroski F)7/9
23.7Safety (Altman Z)2.0
89.6%Growth (Rev YoY)8.6%
1.13Risk (Sharpe 1Y)0.61
0.19xBalance Sheet (D/E)-42.50x
1.23%FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.346
252-Day Correlation
0.317
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricARGXABBV
Market Cap$52.2B$384.7B
P/E Ratio37.1x106.2x
Forward P/E22.7x13.4x
P/B176.61x-57.80x
Dividend Yield3.18%
Beta-0.060.30

Quantitative Metrics

MetricARGXABBV
DCF Fair Value$264.40$126.26
DCF Upside-67.3%-38.9%
Piotroski F5/97/9
Altman Z23.752.01
Beneish M-1.49-2.87
FCF Yield1.23%4.23%
Net Debt/EBITDA-2.6x3.0x
ROIC13.8%8.3%
WACC8.0%7.4%
ROIC – WACC5.8pp0.8pp
Gross Margin89.1%70.2%
Net Margin31.1%6.9%
Rev Growth YoY89.6%8.6%
Sharpe (1Y)1.130.61
Max Drawdown 3Y-38.2%
FCF Payout Ratio65%

ARGX Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

ARGX found in:

IBB3.32%
VGK0.31%
SPDW0.15%
VSGX0.15%
VEA0.15%
CWI0.12%
VEU0.12%
VXUS0.11%
VT0.04%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ARGX vs ABBV: Head-to-Head Analysis

argenx SE (ARGX) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ARGX leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ARGX generates a return on invested capital (ROIC) of 13.8% compared to ABBV's 8.3%. This suggests ARGX is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between ARGX and ABBV is 0.346, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

ARGX appears in 9 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ARGX or ABBV?

Our quantitative analysis compares ARGX and ABBV across nine fundamental dimensions. ARGX wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ARGX and ABBV correlated?

The 252-day correlation between ARGX and ABBV is 0.346. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.